These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35442227)

  • 21. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians.
    Park SK; Moon W; Kim ES; Park SH; Park DI
    Korean J Gastroenterol; 2019 Dec; 74(6):333-340. PubMed ID: 31870139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
    Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
    J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.
    Mahmmod S; Schultheiss JPD; van Bodegraven AA; Dijkstra G; Gilissen LPL; Hoentjen F; Lutgens MWMD; Mahmmod N; van der Meulen-de Jong AE; Smits LJT; Tan ACITL; Oldenburg B; Fidder HH
    Inflamm Bowel Dis; 2021 Nov; 27(12):1954-1962. PubMed ID: 33538298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
    Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease.
    Macaluso FS; Leone S; Previtali E; Ventimiglia M; Armuzzi A; Orlando A;
    Dig Liver Dis; 2020 Nov; 52(11):1304-1309. PubMed ID: 32807691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M; Sciascia S; Roccatello D; Cuadrado MJ
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
    Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients.
    Garcia KS; Facas BP; Machado MB; Teixeira FV; Avedano L; Lönnfors S; Hossne RS; Peyrin-Biroulet L; Queiroz NSF
    Therap Adv Gastroenterol; 2021; 14():17562848211013249. PubMed ID: 34046083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
    Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
    Mazza S; Piazza O Sed N; Conforti FS; Fascì A; Rimondi A; Marinoni B; Casini V; Ricci C; Munari F; Pirola L; Invernizzi P; Girelli C; Lupinacci G; Pastorelli L; Cavallaro F; Ferraris L; Colucci A; Amato A; Eugenio Tontini G; Vecchi M; Fiorino G; Caprioli F
    Clin Transl Sci; 2022 Jan; 15(1):172-181. PubMed ID: 34523800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review.
    Gisbert JP; Chaparro M
    Gastroenterol Hepatol; 2018; 41(6):389-405. PubMed ID: 29753532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.
    Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A
    Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice.
    Armuzzi A; Bouhnik Y; Cummings F; Bettey M; Pieper B; Kang T
    Dig Liver Dis; 2020 Nov; 52(11):1259-1265. PubMed ID: 32601035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN.
    de Ridder L; Assa A; Bronsky J; Romano C; Russell RK; Afzal NA; Hauer AC; Knafelz D; Lionetti P; Strisciuglio C; Veres G; Winter H; Wolters VM; Sladek M; Vulto AG; Dias JA;
    J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):144-153. PubMed ID: 30169454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
    Macaluso FS; Fries W; Viola A; Centritto A; Cappello M; Giuffrida E; Privitera AC; Piccillo G; Magnano A; Vinci E; Vassallo R; Trovatello A; Belluardo N; Giangreco E; Camilleri S; Garufi S; Bertolami C; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Orlando A
    Inflamm Bowel Dis; 2021 Jan; 27(2):182-189. PubMed ID: 32083291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.